Anti-cmet antibody

A technology of antibody and monoclonal antibody, applied in the field of amino acid and nucleic acid sequence, can solve the problem of not describing the data showing any effect of Pfizer antibody

Active Publication Date: 2011-10-26
PIERRE FABRE MEDICAMENT SAS
View PDF22 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

No data are described in this application showing any role of the Pfizer antibody in dimerization of c-Met

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Anti-cmet antibody
  • Anti-cmet antibody
  • Anti-cmet antibody

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0316] Example 1: Production of anti-c-Met antibodies

[0317] To generate anti-c-Met antibody, a cell line expressing c-Met on its plasma membrane transfected with CHO (20×10 6 cells / dose / mouse) subcutaneously immunize 8-week-old BALB / c mice 3 to 5 times, or with c-Met ectodomain fusion protein (R&D Systems, catalog #358MT) (10-15 μg / dose / mouse) Or immunize 8-week-old BALB / c mice with fragments of the recombinant protein for 2 to 3 times. For the first immunization, the fragments of the recombinant protein are mixed with complete Freund's adjuvant, and for subsequent immunizations, with incomplete Freund's adjuvant mix. A mixed protocol in which mice received both CHO-cMet cells and recombinant protein was also performed. Three days prior to cell fusion, mice were boosted i.p. or i.v. with the recombinant protein or fragment. Spleens from mice were then harvested and fused with SP2 / 0-Ag14 myeloma cells (ATCC) and subjected to HAT selection. Four fusions were performed. I...

Embodiment 2

[0323] Example 2: Humanization method of murine 224G11 by CDR-grafting

[0324] 1°) Humanization of the light chain variable domain (VL)

[0325] As a preliminary step, the nucleotide sequence of 224G11VL was compared to the murine germline gene sequence included in the IMGT database (http: / / imgt.cines.fr). Murine IGKV3-5*01 and IGKJ4*01 germline genes have been identified showing 99.31% sequence identity for the V region and 94.28% sequence identity for the J region, respectively. Due to these high homology, the 224G11VL nucleotide sequence was directly used to search for human homology, instead of the corresponding murine germline.

[0326] In a second step, the human germline genes exhibiting the best identity to 224G11VL have been searched to identify the best human candidates for CDR grafting. For selection optimization, alignments between amino acid sequences were performed. The human IGKV4-1*01 germline genes provided 67.30% sequence identity but showed different l...

Embodiment 3

[0333] Example 3: Engineering of Improved Hinge Mutants

[0334] It is well known to those skilled in the art that the hinge region is actively involved in the flexibility of immunoglobulin variable domains (see Brekke et al., 1995; Roux et al., 1997). During the chimerization of 224G11 Mab, the murine constant domain IGHG1 was partially replaced by the equivalent IGHG1 of human origin. Since the amino acid sequences of the hinge regions are highly diverse, "murinization" of the hinge region was performed to preserve its length and rigidity. Since the human IGHG2 hinge region corresponds to the closest homologue of the murine IGHG1 hinge, this sequence was also considered. A series of 7 different hinge sequences (SEQ ID No. 22 to 28) were constructed by incorporating parts of the mouse IGHG1 and human IGHG2 hinges into the human IGHG1 hinge part.

[0335] Another series of hinge mutants (SEQ ID No.58 to 72) was designed and constructed to evaluate the additional cysteine ​​a...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

Disclosed is an antibody capable of binding specifically to the human c-Met receptor and / or capable of specifically inhibiting the tyrosine kinase activity of said receptor, said antibody having an improved antagonistic activity, said antibody comprising a modified hinge region. Disclosed also are a composition comprising such an antibody antagonist to c-Met and its use as a medicament for treating cancer.

Description

technical field [0001] The present invention relates to a novel bivalent antibody capable of specifically binding to human c-Met receptor and / or capable of specifically inhibiting the tyrosine kinase activity of the receptor, as well as the amino acid and nucleic acid sequences encoding the antibody. More particularly, the antibodies according to the invention are capable of inhibiting c-Met dimerization. The invention also includes the use of said antibody as a medicament for the prophylactic and / or therapeutic treatment of cancer or any condition associated with overexpression of said receptor, as well as methods for the diagnosis or treatment of diseases associated with overexpression of c-Met Use in the kit. The present invention finally relates to products and / or compositions comprising these antibodies and other antibodies and / or compounds and / or compounds and / or anticancer agents or agents conjugated to toxins against other growth factors involved in tumor progression ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C07K16/28C07K16/00C07K16/46A61K39/395A61P35/00
CPCA61K2039/505C07K16/00C07K16/2863C07K2317/24C07K2317/53C07K2317/56C07K2317/565C07K2317/73C07K2317/732C07K2317/75C07K2317/76A61P35/00C07K16/40
Inventor L·格奇T·沃琴C·贝斯
Owner PIERRE FABRE MEDICAMENT SAS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap